News | October 11, 2021
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The company plans to expand its portfolio in regulated markets aggressively
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
Next-generation radiofrequency catheter offers first thermal ablation perforator treatment advancement in over 10 years
According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021
The company plans to submit the IND application by the end of 2021
Takeda to exclusively commercialize JR-141 outside the U.S. (except Japan and certain other Asia-Pacific countries) upon regulatory approval
The acquisition complements and strengthens Merck’s cardiovascular pipeline
Subscribe To Our Newsletter & Stay Updated
